Genovis Q2 2023: Strong growth and expanding EBIT margin - Redeye

Redeye continues to see potential for stellar growth ahead for Genovis following its Q2 2023 report, which showcased 40% sales growth coupled with 20% EBIT margins. In this report we discuss the report, recent developments and slightly upwards adjust our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/938707/genovis-q2-2023-strong-growth-and-expanding-ebit-margin?utm_source=finwire&utm_medium=RSS